Akums Drugs & Pharma
Ticker > Company >

Akums Drugs & Pharma share price

Akums Drugs & Pharmaceuticals Ltd.

NSE: AKUMS BSE: 544222 SECTOR: Pharmaceuticals & Drugs  29.46 K   27   13

562.50
+12.25 (2.23%)
BSE: Today, 01:36 PM

Price Summary

Today's High

₹ 592.1

Today's Low

₹ 553.8

52 Week High

₹ 1174.85

52 Week Low

₹ 407.4

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 8853.41 Cr.

Enterprise Value

₹ 8853.41 Cr.

No. of Shares

15.74 Cr.

P/E

26.18

P/B

2.9

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  193.65

CASH

0

DEBT

₹ 0 Cr.

Promoter Holding

75.26 %

EPS (TTM)

₹  21.49

Sales Growth

ROE

ROCE

Profit Growth

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-1.44%
3 Year3.9%
5 Year11.27%

Profit Growth

1 Year43416.08%
3 Year49.93%
5 Year51.1%

ROE%

1 Year18.3%
3 Year11.01%
5 Year3.01%

ROCE %

1 Year17.83%
3 Year11.95%
5 Year7.37%

Debt/Equity

0.0045

Price to Cash Flow

∞

Interest Cover Ratio

0

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 75.26 0.00
Dec 2024 75.26 0.00
Sep 2024 75.26 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 0 days.

 Limitations

  • The company has shown a poor profit growth of 0% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.89727646245317% for the Past 3 years.
  • The company has a low EBITDA margin of 0% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 1019.11 1033.09 1010.41 1055.55
Total Expenditure 891.1 911.9 889.05 961.63
Operating Profit 128.02 121.19 121.37 93.91
Other Income 6.55 13.47 14.56 17.55
Interest 13.02 11.9 5.13 4.54
Depreciation 34.06 34.87 44.52 40
Exceptional Items 0 3.7 4.78 8.22
Profit Before Tax 87.48 91.59 91.05 75.14
Tax 26.27 24.94 24.74 -74.47
Profit After Tax 61.21 66.65 66.31 149.61
Adjustments -1.04 -1.45 -1.13 -1.99
Consolidated Net Profit 60.17 65.21 65.18 147.62
Adjusted EPS (Rs) 4.21 4.26 4.26 9.64

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 2722.63 3671.89 3654.82 4178.18 4118.16
Total Expenditure 2431.46 3763.61 3360.84 4055.2 3657.55
Operating Profit 291.17 -91.72 293.98 122.99 460.61
Other Income 21.16 22.63 90.07 34.03 55.99
Interest 6.74 16.66 46.25 50.61 34.6
Depreciation 69.84 94.68 112.81 125.64 153.45
Exceptional Items -63.82 -12.98 -74.5 -26.03 16.7
Profit Before Tax 171.91 -193.2 150.3 -45.28 345.25
Tax 48.83 57.68 52.48 -46.07 1.48
Profit After Tax 123.09 -250.87 97.82 0.79 343.78
Adjustments -0.38 -1.66 -2.96 -4.83 -5.6
Consolidated Net Profit 122.71 -252.54 94.86 -4.04 338.18
Adjusted EPS (Rs.) 8.57 -17.65 6.63 -0.28 22.09

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 1.3 14.31 28.61 28.61 30.62
Total Reserves 883.55 607.67 688.58 680.89 3016.39
Minority Interest 2.29 3.2 6.19 10.99 16.6
Borrowings 1.16 13.33 115.5 78.3 0
Other N/C liabilities 683.92 1139.27 1130.57 1383.97 -51.98
Current liabilities 579.95 1272.42 1265.57 1210.55 893.75
Total Liabilities 2152.17 3050.2 3235.01 3393.3 3905.38
Assets
Net Block 903.99 1020.54 1097.31 1190.77 1397.37
Capital WIP 17.01 30.82 102.99 195.13 159.62
Intangible WIP 0 0.25 0.16 0.28 3.17
Investments 0.53 0.39 0.14 0.14 0.14
Loans & Advances 43.76 86.1 96.39 56.36 61.41
Other N/C Assets 29.48 48.04 59.14 9.84 9.06
Current Assets 1157.41 1864.06 1878.87 1940.78 2274.61
Total Assets 2152.17 3050.2 3235.01 3393.3 3905.38
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 172.26 -193.2 150.3 -45.28 345.25
Adjustment 144.02 631.42 157.73 556.09 167.71
Changes in Assets & Liabilities -136.84 -351.56 -34.33 49.87 33.47
Tax Paid -45.55 -54.82 -97.06 -62.42 -81.24
Operating Cash Flow 133.89 31.85 176.63 498.26 465.2
Investing Cash Flow -108.87 -234.82 -304.7 -330.8 -547.84
Financing Cash Flow -94.74 236.04 124.54 -108.02 72.79
Net Cash Flow -69.72 33.07 -3.53 59.44 -9.86

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Dec 2024% Mar 2025%
promoters 75.26 75.26 75.26
akums master trust (sanje... - 40.79 40.79
lata jain 0.01 0.01 0.01
sandeep jain 17.24 17.24 17.24
sanjeev jain 17.23 17.23 17.23
akums master trust 40.79 - -
PARTICULARS Sep 2024% Dec 2024% Mar 2025%
investors 24.74 24.74 24.74
franklin india smaller co... 1.71 2.12 3.31
llp 0.01 0.02 0.04
ruby qc investment holdin... 4.62 4.62 4.62
smallcap world fund, inc 2.15 2.15 1.69
akums employee benefits t... 2.73 2.73 -

Annual Reports

Title Link
Title Link
Annual Report 2025

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
Research IDBI Capital

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q1FY25
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q1FY25

Company News

Akums Drugs and Pharmaceuticals informs about AGM and annual report 24 Jun, 5:18 PM Akums Drugs and Pharmaceuticals informs about analyst meet 27 May, 2:43 PM Akums Drugs and Pharmaceuticals reports consolidated net profit of Rs 75.14 crore in Q4 27 May, 11:00 AM Akums Drugs & Pharma - Quaterly Results 26 May, 6:57 PM Akums Drugs & Pharma - Quaterly Results 26 May, 6:57 PM Akums Drugs and Pharmaceuticals informs about board meeting 19 May, 5:29 PM Akums Drugs and Pharmaceuticals informs about annual secretarial compliance report 17 May, 3:24 PM Akums Drugs and Pharmaceuticals informs about resignation of senior management personnel 26 Mar, 3:45 PM Akums Drugs secures patent for 'Benzalkonium Chloride-Free Brinzolamide Ophthalmic Formulation' 15 Feb, 5:00 PM Akums Drugs and Pharmaceuticals informs about newspaper publication 15 Feb, 4:06 PM Akums Drugs and Pharmaceuticals reports 66% drop in Q3 consolidated net profit 7 Feb, 4:27 PM Akums Drugs & Pharma - Quaterly Results 6 Feb, 5:58 PM Akums Drugs & Pharma - Quaterly Results 6 Feb, 5:58 PM Akums Drugs & Pharma - Quaterly Results 6 Feb, 5:58 PM Akums Drugs and Pharmaceuticals informs about analyst meet 3 Feb, 2:58 PM Akums Drugs and Pharmaceuticals informs about disclosure 22 Jan, 12:31 PM Akums Drugs enters into agreement for manufacture, supply of selected pharmaceutical formulations 24 Dec, 3:28 PM Akums Drugs and Pharmaceuticals informs about updates 26 Nov, 5:11 PM Akums Drugs’ arm collaborates with Jagdale Industries 26 Nov, 3:42 PM Akums Drugs enters into exclusive Master Sales Agreement with Caregen 19 Nov, 2:51 PM Akums Drugs and Pharmaceuticals informs about press release 11 Nov, 2:38 PM Akums Drugs & Pharmaceuticals - Quaterly Results 9 Nov, 5:51 PM Akums Drugs & Pharmaceuticals - Quaterly Results 9 Nov, 5:51 PM Akums Drugs & Pharmaceuticals - Quaterly Results 9 Nov, 5:51 PM Akums Drugs and Pharmaceuticals enters into MoU with Government of Republic of Zambia 18 Oct, 2:27 PM Akums Drugs & Pharmaceuticals enters into license & distribution agreement with Triple Hair Inc 16 Oct, 3:45 PM Akums Drugs launches new product Famotidine, Calcium Carbonate and Magnesium Hydroxide 10 Oct, 9:22 AM Akums Drugs and Pharmaceuticals informs about closure of trading window 30 Sep, 12:33 PM Akums Drugs gets patent certificate from Government of India 13 Sep, 10:46 AM Akums Drugs and Pharmaceuticals informs about newspaper publication 26 Aug, 12:41 PM Akums Drugs & Pharmaceuticals - Quaterly Results 24 Aug, 5:30 PM Akums Drugs and Pharmaceuticals informs about earnings call 23 Aug, 2:49 PM Akums Drugs’ arm starts second production facility at Haridwar manufacturing unit 23 Aug, 11:00 AM Akums Drugs and Pharmaceuticals coming with IPO to raise upto Rs 1893.21 crore 27 Jul, 12:58 PM Akums Drugs and Pharmaceuticals gets SEBI’s nod for IPO 9 Jul, 2:40 PM Akums Drugs and Pharmaceuticals files DRHP with SEBI 14 Feb, 12:38 PM
Last Updated on:
Brief about Akums Drugs & Pharma
X